Sign In
Buy XBIO
$3.34
-0.0400 (-1.18%)
At Close: Jun 03, 2026
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
08:05am, Wednesday, 13'th May 2026
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty rev
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
09:00am, Wednesday, 22'nd Apr 2026
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology te
Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast
01:09am, Tuesday, 14'th Apr 2026
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
08:00am, Friday, 13'th Mar 2026
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institut
Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis
01:30am, Wednesday, 04'th Mar 2026
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two compa
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest
03:22am, Thursday, 26'th Feb 2026
Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 55,692 shares, a gr
Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO)
01:24am, Sunday, 01'st Feb 2026
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar
Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)
01:25am, Friday, 30'th Jan 2026
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two c
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest
04:26am, Saturday, 27'th Dec 2025
Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
05:00pm, Thursday, 11'th Dec 2025
Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene
FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
08:45am, Thursday, 13'th Nov 2025
Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHA
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
09:30am, Friday, 10'th Oct 2025
FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
08:00am, Wednesday, 13'th Aug 2025
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the qu
